Clinical Trial Update: Efficacy and Safety of Inotersen in Familial Amyloid Polyneuropathy [Phase 2, Phase 3]

View source ↗

Summary

Phase 2/3 trial results summarize efficacy and safety of inotersen for familial amyloid polyneuropathy (FAP).

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Amyloidosis
• Familial Amyloid Polyneuropathy
• Transthyretin-related Amyloidosis

Drugs mentioned

• Inotersen (inotersen)

Snippet

Sponsor: Ionis Pharmaceuticals, Inc. | Conditions: FAP, Familial Amyloid Polyneuropathy | Phase 2, Phase 3 | Status: COMPLETED | Results posted: 2019-01-23